Relation of Oxidative Stress and Impaired Fibrinolysis with HDL Biogenesis in Indonesian Men with Metabolic Syndrome

Ida Paulina Sormin, Widjaja Lukito, Andi Wijaya, Suryani As'ad

Abstract


BACKGROUND: Biogenesis of HDL involves factors that regulate the synthesis, intravascular remodeling, and catabolism of HDL. Disturbance of these factors can lead to low concentration of HDL-C. Metabolic syndrome (MetS) is characterized by low concentration of high-density lipoprotein cholesterol (HDL-C). In MetS occur several pathological conditions including oxidative stress and impaired fibrinolysis, which contribute to the risk of atherosclerosis process. The correlation between oxidative stress and impaired fibrinolysis with HDL biogenesis dysfunction and its correlation with low concentration of HDL-C has not been well understood and therefore needs to be further investigated.

METHODS: This study was an observational study with crosssectional design, involving 163 adult men, aged 25-60 years with metabolic syndrome. Concentration of apoA-1, prebeta-1 HDL, CETP, F2-isoprostan, PAI-1, and HDL-C were measured. The apo A1/HDL ratio indicated HDL maturation, whereas the CETP/HDL-C and CETP/TG ratios indicated HDL catabolism.

RESULTS: The study showed that there were a positive correlation between PAI-1 with apoA1/HDL-C ratios (r=0.226, p=0.005) and a negative correlation with the CETP/TG ratios (r=-0.215, p=0.007), whereas F2-isoprostan did not have correlation with HDL biogenesis factors.

CONCLUSIONS: We concluded that there was correlation between impaired fibrinolysis with decreased HDL maturation and there was increased HDL catabolism leading to low HDL-C concentration in men with metabolic syndrome.

KEYWORDS: F2-isoprostan, PAI-1, apoA-1, prebeta-1 HDL, CETP, metabolic syndrome


Full Text:

PDF

References


Ashen MD, Blumenthal RS. Low HDL cholesterol levels. N Engl J Med. 2005; 353: 1252-60, CrossRef.

Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res.2005; 96: 1221-32, CrossRef.

Fredenrich A, Bayer P. Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. Diabetes Metab. 2003; 29: 201-5, CrossRef.

Barter PJ, Brewer Jr HB, Chapman MJ. Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis. Atheroscler Thromb Vasc Biol. 2003; 23: 160-7, CrossRef.

Deen D. Metabolic Syndrome: time for action. Am Fam Physician. 2004; 69: 2875-82, PMID.

Tang W, Hong Y, Province MA, Rich SS, Hopkins PN, Arnett DK, et al. Familial clustering for features of the metabolic syndrome: The National Heart, Lung, and Blood Institute (NHLBI) Family Heart study. Diabetes Care. 2006; 29: 631-6, CrossRef.

Badan Penelitian dan Pengembangan Depkes RI. Survey Kesehatan Nasional, Survey Kesehatan Rumah Tangga (SKRT). 2004. Jakarta: Depkes RI; 2004.

Tawakol R. High-density lipoprotein cholesterol - The next battle front in the fight against heart disease. Business briefing: US Cardiology. 2004, article.

Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional high-density liporotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab. 2004; 89: 4963-71, CrossRef.

Alberti KG, Zimmet P, Shaw J. IDF epidemiology task force consensus group: The metabolic syndrome: a new worldwide definition. Lancet 2005; 366: 1059-62, CrossRef.

Dorland WAN. Dorland’s illustrated medical dictionary. 26th ed. Philadelphia: W.B. Saunders Company; 1981, NLMID.

Lawrence GS. Interaksi asam lemak bebas, status anti oksidan total, plasminogen activator inhibitor-1, adiponektin, dan high sensitivity C-reactive protein terhadap kajian toleransi glukosa terganggu [dissertation]. Makassar: Universitas Hassanuddin; 2004.

Parini P, Rudel LL. Is there a need for cholesteryl ester transfer protein inhibition? Atheroscler Thromb Vasc Biol. 2003; 23: 374-5, CrossRef.

Kontush A, Chapman J. Functionally defective highdensity lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, infl ammation, and atherosclerosis. Pharmacol Rev. 2006; 58 : 342-74, CrossRef.

Skurk T, Hauner H. Obesity and impaired fibrinolysis; role of adipose production of plasminogen activator inhibitor-1. Int J Obes. 2004; 28: 1357-64, CrossRef.

Pont F, Duvillard L, Florentin E, Gambert P, Verges B. High density lipoprotein apolipoprotein A-I kinetics in obese insulin resistant patients. An in vivo stable isotope study. Int J Obes. 2002; 26: 1151-8, CrossRef.

Chan DC, Barrett PH, Watts GF, Recent Studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol. 2006; 17: 28- 36, CrossRef.

Chan DC, Barrett PH, Watts GF, Lipoprotein transport in the metabolic syndrome: Pathophysiological and interventional studies employing stable isotop and modelling methods. Clin Sci. 2004; 107: 233-49, CrossRef.




DOI: https://doi.org/10.18585/inabj.v2i1.110

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute